Richter transformation in 16 of 149 Chinese patients with chronic lymphocytic leukemia

References

• Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer 2005;103:216–228.
   PubMed Web of Science ®Google Scholar
• Lortholary P, Ripault M, Boiron M. Richter's syndrome. Nouv Rev Fr Hematol 1964;72:456–457.
   Google Scholar
• Harousseau JL, Flandrin G, Tricot G, . Malignant lymphoma supervening in chronic lymphocytic leukemia and related disorders. Richter's syndrome: a study of 25 cases. Cancer 1981;48:1302–1308.
   PubMed Web of Science ®Google Scholar
• Robertson LE, Pugh W, O'Brien S, . Richter's syndrome: a report on 39 patients. J Clin Oncol 1993;11:1985–1989.
   PubMed Web of Science ®Google Scholar
• Montillo M, Hamblin T, Hallek M, . Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica 2005;90:391–399.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, . WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.
   Google Scholar
• Xu W, Cao X, Miao KR, . Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors. Int J Hematol 2009;90:205–211.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhang Y, Zheng W, . Distinctive IgVH gene segments usage and mutation status in Chinese patients with chronic lymphocytic leukemia. Leuk Res 2008;32:1491–1498.
   PubMed Web of Science ®Google Scholar
• Xu W, Li JY, Wu YJ, . CD38 as a prognostic factor in Chinese patients with chronic lymphocytic leukaemia. Leuk Res 2009;33: 237–243.
   PubMed Web of Science ®Google Scholar
• Mayr C, Speicher MR, Kofler DM, . Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006;107:742–751.
   PubMed Web of Science ®Google Scholar
• Shaffer LG, Tommerup N. An international system for human cytogenetic nomenclature. Basel: ISCN; 2005.
   Google Scholar
• Qiu HX, Xu W, Cao XS, . Cytogenetic characterisation in Chinese patients with chronic lymphocytic leukemia: a prospective, multicenter study on 143 cases analysed with interphase fluorescence in situ hybridisation. Leuk Lymphoma 2008;49:1887–1892.
   PubMed Web of Science ®Google Scholar
• Dong HJ, Zhou LT, Zhu DX, . The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13). Ann Hematol 2011;90:709–717.
   PubMedGoogle Scholar
• Richter MN. Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia. Am J Pathol 1928;4:285–292.
   PubMedGoogle Scholar
• Rossi D, Cerri M, Capello D, . Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol 2008;142:202–215.
   PubMed Web of Science ®Google Scholar
• Montoto S, Davies AJ, Matthews J, . Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007;25:2426–2433.
   PubMed Web of Science ®Google Scholar
• Rossi D, Rasi S, Capello D, . Prognostic assessment of BCL2–938C > A polymorphism in chronic lymphocytic leukemia. Blood 2008;111:466–468.
   PubMed Web of Science ®Google Scholar
• Rossi D, Zucchetto A, Rossi FM, . CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. Haematologica 2008;93:1575–1579.
   PubMed Web of Science ®Google Scholar
• Deambrogi C, Cresta S, Cerri M, . 14q32 translocations and risk of Richter transformation in chronic lymphocytic leukaemia. Br J Haematol 2009;144:131–133.
   PubMed Web of Science ®Google Scholar
• Maddocks-Christianson K, Slager SL, Zent CS, . Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol 2007;139:398–404.
   PubMed Web of Science ®Google Scholar
• Aydin S, Rossi D, Bergui L, . CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome? Blood 2008;111:5646–5653.
   PubMed Web of Science ®Google Scholar
• Rossi D, Gaidano G. Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol 2009;27:1–10.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, O'Brien S, Khouri I, . Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 2006;24:2343–2351.
   PubMed Web of Science ®Google Scholar
• Rossi D, Spina V, Deambrogi C, . The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 2011;117:3391–3401.
   PubMed Web of Science ®Google Scholar
• Dabaja BS, O'Brien SM, Kantarjian HM, . Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome. Leuk Lymphoma 2001;42:329–337.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, O'Brien SM, Cortes JE, . Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma 2002;43:767–772.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Kantarjian HM, Cortes J, . Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 2003;97:1711–1720.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wierda WG, Plunkett W, . Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008;26:196–203.
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Keating MJ, O'Brien S, . Allogeneic haematopoietic transplantation for Richter's syndrome. Br J Haematol 2000;110: 897–899.
   PubMed Web of Science ®Google Scholar